Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World study checks how well oral semaglutide controls diabetes

NCT ID NCT04601740

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times

Summary

This study followed 145 adults with type 2 diabetes who were prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months. Participants also filled out questionnaires about how they took the medication. The goal was to see how well the drug works in real-world conditions, not in a controlled lab setting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Master Centre Netherlands

    Alphen aan den Rijn, 2408 AV, Netherlands

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

oral semaglutide (Rybelsus)

What this could lead to

If successful, this could confirm that oral semaglutide effectively lowers blood sugar and helps with weight loss in everyday clinical practice for type 2 diabetes.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or adherence. It does not test a new drug, only gathers real-world data.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.